Metabolon, Inc., the leader in metabolomics-driven biomarker discovery and analysis, has announced the continuation and expansion of a multi-study agreement with Mitsubishi Tanabe Pharma, a global and research-driven pharmaceutical company.

The expanded partnership will give researchers at Mitsubishi Tanabe preferred access to Metabolon's global biochemical profiling services.

Completing research studies using Metabolon's services, Mitsubishi Tanabe has gained insight into new drugs and streamlined their development. As part of the new agreement, Mitsubishi Tanabe has committed several upcoming research studies to Metabolon.

"For progressive partners like Mitsubishi Tanabe, we are able to offer the fastest turn-around of valuable biochemical information that the research groups at Mitsubishi Tanabe are seeking," commented John Ryals, president and CEO of Metabolon. "Expanding relationships like this one with Mitsubishi Tanabe is continued validation of Metabolon's ability to impact the development of drugs and diagnostics."

Metabolon and Mitsubishi Tanabe are in the process of publishing joint study results in peer-reviewed publications and have presented posters at events like The Society of Toxicology. Some of these results were also outlined in a recent webinar hosted by Metabolon. Please visit www.metabolon.com for more information about these and other research published by Metabolon's clients.

Metabolon is a diagnostics and services company offering the industry's leading biochemical profiling platform. Metabolon's patented platform provides a global analysis of complex biological samples for the discovery of markers and pathways associated with drug action and disease.

Mitsubishi Tanabe Pharma Corporation, one of the leading pharmaceutical companies in Japan, specializes in developing and marketing globally competitive pharmaceutical products in the fields of cardiovascular and metabolic diseases, brain and nerve diseases, and renal and urinary system diseases.